-
Mashup Score: 8Targeting T cells with tetravalent bispecific antibodies for the treatment of graft-versus-host disease - 3 day(s) ago
Key PointsCD3×CD3 tetravalent antibodies cure GVHD in xenogeneic mouse models and warrant further investigation in more clinically relevant models.
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 18
Program: Late-breaking Abstracts Session: Late-Breaking Abstracts Session Hematology Disease Topics & Pathways: Research, Clinical trials, Lymphomas, Non-Hodgkin lymphoma, Clinical Research, B Cell lymphoma, Diseases, Lymphoid Malignancies 1 Medica l College of Wisconsin, Milwaukee, WI 2 Dana-Farber Cancer Institute / ECOG-ACRIN Biostatistics, Bostin, MA 3 Fred Hutchinson Cancer Center, University of Washington, Seattle, WA 4 Emory University / Winship Cancer Institute, Atlanta, GA 5 University of
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
Stop ASCT for MCL...another evidence https://t.co/MyUi5Xj692
-
-
Mashup Score: 52
Given the selection of elderly patients with AML in first complete remission (CR1) the advantage of consolidation with allogeneic hematopoietic cell transplantation (HCT) over chemotherapy is still unclear. Newly diagnosed AML patients in CR1 aged 60-75 years were registered and a donor search initiated. After one consolidation cycle, patients with a matched donor were randomized to HCT with fludarabine/low-dose total body irradiation and cyclosporine/mycophenolate mofetil immunosuppression or conventional non-HCT. Primary outcome was restricted mean leukemia-free survival (RM-LFS) up to 5 years. Between 2010 and 2017, 245 patients (median age 67 years) were registered at CR1. After one consolidation, 26.9% of patients failed inclusion criteria. Of the 179 (73%) patients still on study, 75.4% had an HLA identical donor. Ten ineligible patients were excluded, and 125 randomized to HCT (N=83) or non-HCT (N=42). The primary outcome RM-LFS up to 5 years was 24.5 months (95% confidence inte
Source: haematologica.orgCategories: General Medicine News, Hem/OncsTweet-
Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study | Haematologica https://t.co/LCXab2JBEb
-
-
Mashup Score: 1
While there is growing consensus that real-world data should play a larger role in generating causal evidence for health care, it is less clear whether and how AI can help. Current approaches to AI…
Source: ai.nejm.orgCategories: General Medicine News, Hem/OncsTweet-
Artificial Intelligence–Based Copilots to Generate Causal Evidence | NEJM AI https://t.co/WmpW50EjZb
-
-
Mashup Score: 21Dynamics of Immune Reconstitution and Impact on Outcomes Across CAR-T Cell Products in Large B-Cell Lymphoma - 1 month(s) ago
Abstract. Patients treated with chimeric antigen receptor T-cell (CAR-T) therapy are subject to profound immune suppression. Dynamics of immune reconstitution (IR) and impacts of IR on outcomes following infusion across CAR-T products are not well understood. Here, we profiled IR in 263 patients with relapsed/refractory large B-cell lymphoma receiving CAR-T therapy (axicabtagene ciloleucel 44.9%, lisocabtagene maraleucel 30.4%, tisagenlecleucel 24.7%). Following infusion, patients remain persistently immunosuppressed, with 48.1% having CD4+ T cell counts <200/µL and median CD3-19+ B cell counts remaining zero through 1 year after CAR-T. IR differences exist by product, with fastest CD4+ T cell recovery seen for tisagenlecleucel, driven primarily by more rapid recovery of the CD4+CCR7-45RA- effector memory subset. Natural killer cell, but not CD4+ T cell, recovery is significantly associated with favorable progression-free (HR: 0.647; 95% CI: 0.476-0.880) and overall survival (HR: 0.637
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet-
Dynamics of Immune Reconstitution and Impact on Outcomes Across CAR-T Cell Products in Large B-Cell Lymphoma https://t.co/T7nngYI5wM
-
-
Mashup Score: 8
As the number of recipients of chimeric antigen receptor (CAR) T-cell therapies has rapidly increased, sporadic reports of T-cell lymphomas arising de novo
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
T-cell lymphomas in recipients of CAR-T cells: assessing risks and causalities https://t.co/UrKaHjDus1
-
-
Mashup Score: 19Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma - 1 month(s) ago
Key PointsA lower circulating lymphocyte-to-monocyte ratio and proportion of B cells at apheresis predict a reduced likelihood of response to CAR-T.On expl
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma https://t.co/cUSP8Ppr0E
-
-
Mashup Score: 2
Severe hemophilia A is managed with factor VIII replacement or hemostatic products that stop or prevent bleeding. Data on gene therapy with hematopoietic stem-cell (HSC)–based expression of factor …
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet-
Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A | New England Journal of Medicine https://t.co/MFaDJ0giEE
-
-
Mashup Score: 10
Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma, a…
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet-
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma | New England Journal of Medicine https://t.co/8LytRpPtLE
-
-
Mashup Score: 1Elías Campo: "El coneixement generat durant vint anys de recerca al projecte del genoma de la leucèmia comença a arribar al pacient" - 2 month(s) ago
Director de l’IDIBAPS i catedràtic de la UB
Source: www.ara.catCategories: General Medicine News, Hem/OncsTweet-
https://t.co/uqe1KNBt81
-
Targeting T cells with tetravalent bispecific antibodies for the treatment of graft-versus-host disease https://t.co/bVNeHi93dg